WO2000039280A8 - Leukocyte-derived interferon preparations - Google Patents
Leukocyte-derived interferon preparationsInfo
- Publication number
- WO2000039280A8 WO2000039280A8 PCT/US1999/031198 US9931198W WO0039280A8 WO 2000039280 A8 WO2000039280 A8 WO 2000039280A8 US 9931198 W US9931198 W US 9931198W WO 0039280 A8 WO0039280 A8 WO 0039280A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alpha
- leukocyte
- omega
- natural type
- interferon preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99967753A EP1140144A4 (en) | 1998-12-31 | 1999-12-29 | Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/224,895 | 1998-12-31 | ||
US09/224,895 US6350589B1 (en) | 1998-12-31 | 1998-12-31 | Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods |
US09/229,039 US6433144B1 (en) | 1999-01-12 | 1999-01-12 | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
US09/229,039 | 1999-01-12 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2000039280A2 WO2000039280A2 (en) | 2000-07-06 |
WO2000039280A8 true WO2000039280A8 (en) | 2000-10-19 |
WO2000039280A3 WO2000039280A3 (en) | 2001-07-19 |
WO2000039280A9 WO2000039280A9 (en) | 2001-08-23 |
Family
ID=26919102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/031198 WO2000039280A2 (en) | 1998-12-31 | 1999-12-29 | Leukocyte-derived interferon preparations |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1140144A4 (en) |
WO (1) | WO2000039280A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002225870B2 (en) | 2000-11-03 | 2006-09-21 | Intarcia Therapeutics, Inc. | Method for short-term and long-term drug dosimetry |
FR2822845B1 (en) | 2001-03-30 | 2003-12-12 | Genodyssee | NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES |
FR2823764B1 (en) * | 2001-04-24 | 2003-12-12 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN ALPHA-17 GENE |
FR2825716B1 (en) * | 2001-06-11 | 2004-09-24 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES FROM IFN ALPHA 7 |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
AU2006212012B2 (en) | 2005-02-12 | 2011-10-13 | Swedish Orphan Biovitrum International Ab | Methods and uses of antibodies in the purification of interferon |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
RU2482871C2 (en) * | 2010-06-07 | 2013-05-27 | Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") | Composition for treating viral diseases in animals |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
EP0625991B1 (en) * | 1992-02-10 | 1999-04-28 | Interferon Sciences, Inc. | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
EP0626448A3 (en) * | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Process for preparing and purifying alpha-interferon |
EP1104809A1 (en) * | 1994-04-09 | 2001-06-06 | F. Hoffmann-La Roche Ag | Process for producing alpha-interferon |
-
1999
- 1999-12-29 EP EP99967753A patent/EP1140144A4/en not_active Withdrawn
- 1999-12-29 WO PCT/US1999/031198 patent/WO2000039280A2/en not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Also Published As
Publication number | Publication date |
---|---|
EP1140144A2 (en) | 2001-10-10 |
WO2000039280A3 (en) | 2001-07-19 |
EP1140144A4 (en) | 2002-10-30 |
WO2000039280A2 (en) | 2000-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000039280A8 (en) | Leukocyte-derived interferon preparations | |
DK1032662T3 (en) | Methods and Compositions for Immunomodulation | |
CY1112927T1 (en) | ANTI-ANTI-ANTI-ILL-12 | |
WO1998033509A3 (en) | Useful properties of human lactoferrin and variants thereof | |
DE69718811D1 (en) | METHOD FOR THE QUICK IN-SITU ANALYSIS OF SELECTED COMPONENTS OF HOMOGENEOUS SOLID COMPOSITIONS, IN PARTICULAR PHARMACEUTICAL COMPOSITIONS | |
ATE383169T1 (en) | COMPONENT AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS | |
TR199802305T2 (en) | Cheek application method. | |
TR199903331T2 (en) | Farnesil protein transferase inhibitors. | |
TR199701071T2 (en) | Compounds and compositions for delivery of the active substance. | |
IL112664A0 (en) | 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
BR9807577A (en) | Method to prevent and delay the onset of Alzheimer's disease and its composition | |
EE9700081A (en) | Keratinocyte growth factor analogues | |
DK1165537T3 (en) | Hydroxymatairesinol for cancer prevention | |
ATE426397T1 (en) | COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION | |
FI972703A (en) | Recombinant IL-5 antagonists useful in the treatment of IL-5-related diseases | |
AU2284299A (en) | Lipopeptides containing an interferon fragment and uses thereof in pharmaceutical compositions | |
ATE234111T1 (en) | THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA | |
WO1999059617A3 (en) | Immunoregulator | |
WO2001068697A3 (en) | Methods and compositions for immunoregulation | |
BRPI0309421A8 (en) | METHOD OF PREPARING A FOODSTUFFS AND COMPOSITION TO TREAT OR PREVENT HYPERCHOLESTEROLEMIA | |
SE9603725D0 (en) | New teatment | |
EP0716591A4 (en) | METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS | |
WO1996013498A3 (en) | L-erythrosyl nucleosides | |
HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant | |
NZ235497A (en) | Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AT AU BR CA CH CN DE DK ES FI GB IL IN JP KR MX NO RU SE TR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AT AU BR CA CH CN DE DK ES FI GB IL IN JP KR MX NO RU SE TR |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 27/2000 UNDER (81) ADD "AE, AU, BR, CA, CN, IL, IN, JP, KR, MX, NO, RU, TR"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AT AU BR CA CH CN DE DK ES FI GB IL IN JP KR MX NO RU SE TR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999967753 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-32, DESCRIPTION, REPLACED BY NEW PAGES 1-33; PAGES 33-39, CLAIMS, REPLACED BY NEW PAGES 34-40; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 1999967753 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999967753 Country of ref document: EP |